Background: Due to improved outcomes in breast cancer (BCa), the proportion of affected women dying of other causes has increased. Thus, a better survival of BCa requires knowledge of other causes of death.
introduction
Estimates of the percentage of breast cancer (BCa) patients that die of BCa itself have varied substantially, ranging between 50% and 76% of all deaths [1] [2] [3] [4] [5] [6] . Elderly BCa patients are less likely to have BCa as the underlying cause [7] because they tend to have less aggressive cancers and have higher mortality from other causes [4] . Patients with higher grade [6] and higher stage [8] are likely to have BCa as the underlying cause. Deaths shortly after diagnosis are more likely due to BCa [6] . Recently, the ageadjusted incidence of BCa has increased drastically, most notably after the introduction of mammographic screening in the late eighties [9] . However, mortality from BCa has remained constant or even declined in some countries. Consequently, other causes are playing a greater role in the mortality of BCa patients. Especially, diabetes has been shown to increase mortality among BCa patients [10] . The success in fighting BCa and improving the quality of life of affected patients thus requires more focus on comorbidities and co-mortalities.
Although cause-specific mortality from BCa among BCa patients is well documented, cause-specific mortality from other death causes has been investigated to a lesser extent. We are aware of one Australian study investigating cause-specific mortality from other causes. This study has reported that BCa patients do not have a higher mortality from any specific cause [11] . The aim of the present study was to investigate whether BCa patients have a higher risk of dying of other diseases and conditions, compared with women without BCa. The nationwide Swedish Family-Cancer Database was used to calculate hazard ratios (HRs) for both the underlying and multiple causes of death. Results may motivate health care providers to draw greater attention toward comorbidities affecting their BCa patients.
materials and methods
The Swedish Family-Cancer Database was first created in 1996 by the linking of the Swedish Cancer Database and the Swedish Multigeneration Database [12] . Since 2006, the Swedish Family-Cancer Database has been a subdataset of the MigMed database located at the Center for Primary Health Care in Malmö, Sweden. The MigMed database includes cancer and mortality data from The National Board of Health and Welfare (e.g. Cancer Registry and Swedish Mortality Registry) and socioeconomic data from Statistics Sweden (the Population Registry and the Multigeneration Registry). All individuals that are born in Sweden after 1931 or have immigrated to Sweden since then are included in the Database, along with their biological parents [13] , totaling 11.8 million individuals. The total amount of cancer diagnoses (diagnosed until 2006) exceeds 1 million. The 'International Classification of Diseases' (ICD) is the basis of death cause coding. The underlying cause is chosen according to World Health Organization guidelines and is ''the disease or injury which initiated the train of morbid events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury'' [14] . The multiple causes include complications and other conditions possibly contributing to death.
The study time was 1987-2006 because since 1987 all deaths were coded according to two easily comparable codings: ICD-9 (used 1987 ICD-9 (used -1996 and ICD-10 (used since 1997). All women born before 1977 who resided in Sweden during the study time were included. Individuals in the BCa group were those who were 'diagnosed with breast cancer (ICD-7 code 170) as the first invasive cancer'. All other women were part of the reference group. A Cox regression model with age as the underlying timescale was used to calculate HRs for dying of a specific cause, comparing BCa patients with all other women. Calculations were carried out with SAS software (PROC PHREG; SAS Version 9.2; SAS Institute, Cary, NC). Entry times were immigration, presence at census, or in January 1987, whichever occurred last. Censoring events were December 2006, emigration, absence at census, or death from another cause than the cause of interest. Underlying and multiple causes of death were analyzed separately. First, calculations were made on the underlying causes only, the event of interest being death from a specific underlying cause. Then, the multiple causes were taken into consideration, although without any regard of the number of death causes. The event of interest was to die with a specific condition listed among the multiple causes. The aforementioned calculations were made separately using time since diagnosis of BCa (<5, between 5 and 10, >10 years) as a time-dependent variable. Finally, the number of death causes was also taken into consideration, and it could thus be investigated whether some death causes are more frequent in BCa patients with few causes or those with many causes. In these calculations, having a specific number of death causes was defined as an additional criterion for the event of interest. The socioeconomic index and geographical region of residence were included as covariates in all calculations.
death cause definitions
ICD codes used in the disease categories were the following (ICD-10; ICD-9): Cerebrovascular accident (I60-I69; 430-438), Myocardial infarction (I21-I22; 410), Other coronary heart diseases (I20, I23-I25; 411-414), Dementia (F00-F03, G30; 290, 331.0), Heart failure (I50; 428), Other heart disease (I30-I49, I52; 420-427), Pneumonia (J10-J18; 480-487), Arterial disease (I70-I79; 440-448), Gastrointestinal disease (K00-K93; 520-579), External causes (S00-T98, V01-Y98; 800-900, e800-e999), Complications of diagnostic or surgical procedures (Y60-Y84; e870-e879), Complications of therapeutic drug or vaccine usage (Y40-Y59; e930-e949), Suicide (X60-X84; e950-e959), Traffic accident (V01-V99; e800-e848), Falls (W00-W19; e880-e888), Chronic lower respiratory disease (J40-J49; 490-496), Symptoms (R00-R99; 780-799), Diabetes (E10-E14; 250), Pulmonary circulation (I26-I28, J81; 415-417, 514), Urinary system disease (N00-N39; 580-599), Nervous system disease (G00-G99, except G30; 320-359, except 331.0), Complications of heart disease (I51; 429), Hypertensive disease (I10-I19; 401-405), Other bacterial disease (A30-A49; 030-041), Psychic disease (F04-F99; 291-319), Anemia (D50-D64; 280-285), Other tumors than breast cancer (C00-D48, excluding C50, C77-C80, and C97; 140-239, excluding 174, [196] [197] [198] [199] , and Breast cancer (C50; 174).
results
Of the 3.68 million subjects, the number of deceased was 0.64 million. Among the 122 000 BCa patients, 48 000 had died. BCa was the underlying cause in 46% of deceased BCa patients. Other important causes of death were cerebrovascular diseases, various heart diseases, and dementia. In the initial calculations, HRs were calculated for the underlying causes ( Table 1 ). The highest HR was identified for pulmonary circulation (1.51), followed by heart failure (1.29). Differences were noticed when comparing specific HRs for different periods since diagnosis (data not shown). We found a decreased hazard for myocardial infarction within the first 5 years after diagnosis {0. In analyses on the multiple causes of death, the number of death causes was initially not considered. External causes (1.86) with several subgroups featured high HRs. The category 'external causes' includes various events, such as accidents, suicide, and iatrogenic causes. Also, pulmonary circulation (1.83) and gastrointestinal disease (1.68) feature high HRs.
In further analyses, the multiple death causes were investigated by distinguishing them depending on the number of death causes (Table 2 ). Gastrointestinal disease (2.80), pulmonary circulation (2.51), and subcategories of external causes featured the highest HRs when being one of the two listed death causes.
Finally, analyses were made depending on the laterality of the malignancy on several cardiovascular death causes (Table  3) . Tumor laterality did not have a statistically significant effect on the underlying cause of death. However, BCa patients with a left-sided tumor had a substantially increased risk to have cerebrovascular accidents listed among the multiple causes of death, compared with those with a rightsided tumor. A similar increased risk was also found for heart failure and arterial disease.
discussion
We used data from a nationwide database to investigate death causes in BCa patients. We found that compared with all other women, BCa patients are at an increased risk to die of various cardiac diseases, external causes, and diseases of pulmonary circulation. We also found BCa patients to be at an increased risk of dying with a gastrointestinal disease among the listed multiple causes. The highest HRs for most causes were seen among decedents with only two listed death causes. To our knowledge, our study is the first to calculate cause-specific HRs for a wide spectrum of death causes, comparing BCa patients with all other women. Our study design differs substantially from previous studies. For example, one study has investigated probabilities of death from BCa and non-BCa causes in BCa patients with different characteristics [8] . Proportions of various death causes among BCa patients have also been investigated [6] . Finally, the impact of comorbidities on survival has also been analyzed in numerous trials [10, 15, 16] . One advantage in our study over previous studies is the consideration of both the underlying and multiple causes of death. Although the reliability of the underlying cause is most likely higher than that of the multiple causes, these may be used complementary to each other. Multiple causes of death contribute to mortality and show the spectrum of comorbidities, and it has earlier been pointed out that deaths seldom only have one cause [17] . Furthermore, considering only the underlying cause of death will omit an excessive amount of available data.
When interpreting our results, it is worth noting that the present approach disregards whether BCa precedes a condition or vice versa. Therefore, we can conclude that BCa patients have an increased risk of dying of the diseases featuring high HRs but cannot infer causality. In some cases, the comorbidity might as well precede BCa. For example, one study has concluded that women with diabetes may have an increased risk for developing BCa, indicating that diabetes precedes BCa [18] . In contrast, literature clearly suggests that BCa precedes pulmonary embolism and heart failure, which will be discussed below. The reliability of death certificates also has implications for our study. The physician that issues the death certificate may vary depending on the place of death. Between 1997 and 2003, 34%-38% of Swedish women >65 HR, hazard ratio; Bca, breast cancer; CI, confidence interval, CHD, coronary heart diseases. years died in hospitals [19] . Although very limited data are available on death locations of Swedish BCa patients, we believe that a majority of terminally ill BCa patients are nursed in hospitals or hospices. A British study has reported that approximately half of BCa patients died at hospitals [20] .
In the following sections, some possible mechanisms explaining our findings of increased risks are discussed.
diseases of pulmonary circulation
The major cause of death in this category, which featured increased risks, is pulmonary embolism, often caused by venous thromboembolism. The name Trousseau's syndrome is sometimes used when referring to the widely known relationship between malignant disease and venous thromboembolism [21, 22] . It has many proposed mechanisms. For example, cancer cells can produce pro-coagulative enzymes or inflammatory cytokines, leading to a prothrombotic state.
Several treatments of BCa have been associated with an increased incidence of venous thrombotic events. For example, the estrogen receptor modulator tamoxifen is widely recognized to have a thrombotic effect. A Danish study has found that women treated with tamoxifen have a higher risk (HR = 2.5) to develop pulmonary embolism or deep venous thrombosis during the first 5 years after initiation of treatment, compared with a nontreatment cohort [23] . Similar results have been described by Cuzick et al. (risk ratio = 2.26) [24] . The risk is highest in the first 2 years after treatment has commenced but decreases during the subsequent years [23] . We also found that the risk is higher shortly after diagnosis, thus confirming these previous findings. Chemotherapy also increases the risk of venous thromboembolism, for example by damaging the endothelium or increasing the levels of pro-coagulative substances [25] . Finally, surgery is a well-known risk factor for thrombotic events [26] .
gastrointestinal disease
Several diseases that are included in this category can be connected to BCa. BCa frequently metastasizes to the liver, which may cause hepatic failure with associated sequels [27] . Furthermore, liver metastases are associated with a bad prognosis; therefore, these patients are likely to die earlier.
Ileus is a potential complication in surgical patients and is thought to be caused by heightened sympathetic activity, which is usually present postoperatively [28] . Also contributing to the pathogenesis of ileus is opioid usage, which lowers intestinal motility [29] . Not much data are available on hepatotoxicity in BCa therapy. However, tamoxifen has been showed to have hepatotoxic effects in BCa patients with preexisting liver steatosis [30] .
external causes
This is a wide category containing various events, such as fractures, suicide, or accidents. Various treatments of BCa have been associated with lower bone mineral density, thereby increasing the risk of fractures. Chemotherapy in postmenopausal BCa patients has been associated with a decrease in bone mineral density [31] . Both direct and indirect mechanisms lowering bone mineral density in chemotherapy are proposed. 'Direct' mechanisms refer to direct toxic effects from chemotherapy on bone. Chemotherapy-mediated damage to the ovaries can cause an 'indirect' decrease in circulating estrogen levels, which by regulating osteoclasts plays an important role in bone physiology. Estrogen levels are also lowered by aromatase inhibitors [32, 33] . Fractures have been shown to be more common in BCa patients treated with letrozole, an aromatase inhibitor, than BCa patients treated with tamoxifen, which features a protective effect on bone (in 9.3% against 6.5% in one study [32] ; 8.0% against 5.4% in another study [33] ). Bone metastases also increase bone turnover, causing increased fragility and a tendency toward fractures [34] .
cardiovascular disease
We found no association between BCa and myocardial infarction in non-time-dependent analyses. However, the risk was smaller <5 years after diagnosis compared with >10 years after diagnosis. We found risk increases in other cardiovascular diseases to be more noticeable, especially heart failure. Cardiac toxicity in BCa treatment is widely documented. Radiotherapy is associated with increased cardiovascular mortality in treated women, and women with a left-sided tumor who are treated with radiotherapy have a higher mortality than those with original articles Annals of Oncology a right-sided tumor [35] [36] [37] . The increased risk is higher in women treated in the 1970s than in those that have been treated more recently. The cardiotoxic effects often manifest themselves a long time (>10 years) after treatment; therefore, it is important that new studies are made on BCa patients treated with radiotherapy during the last decades to get updated information on the toxicity of modern radiotherapy [37, 38] . The late onset of effects might also be the reason to why it has also been reported that there is no association between radiotherapy and myocardial infarction [39] . The HER2 antibody trastuzumab has also been associated with increased cardiotoxicity in BCa patients, although the risk is very small when used in monotherapy [39] . In combination therapy with anthracyclines, which also feature cardiotoxicity, a synergistic effect on cardiac toxicity has been found [39, 40] . As many as 27% of BCa patients treated with this combination have been shown to develop congestive heart failure [40] . Synergistic effects have also been shown in combination treatment with anthracyclines and taxanes [41] . The mechanism behind the synergistic effect of taxanes and anthracyclines is thought to be via pharmacokinetic interactions. In contrast, cardiotoxicity in trastuzumab-anthracycline treatment is suggested to be due to inhibition of the HER2-activated pathway. This pathway is protective in cardiac stress, for example induced by anthracyclines.
We conclude that BCa patients have an increased risk to die of several diseases than other women. The highest risks are for diseases of pulmonary circulation, various external causes, and several heart diseases, most notably heart failure. The risk patterns vary depending on time since diagnosis and laterality of the malignancy. Mechanisms have been described attributing the increased risks to both treatment and BCa itself. Future improvements in BCa survival require more attention toward comorbidities. 
